 | Up a level |
Stavrou, Victoria, Fultang, Livingstone 
ORCID: 0000-0002-8215-6660, Booth, Sarah, De Simone, Daniele, Bartnik, Arekdiusz, Scarpa, Ugo, Gneo, Luciana, Panetti, Silvia, Potluri, Sandeep, Almowaled, Meaad et al (show 13 more authors)
(2023)
Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment.
Cancer immunology, immunotherapy : CII, 72 (3).
pp. 543-560.
Russell, Nigel H, Hills, Robert K, Thomas, Abin, Thomas, Ian, Kjeldsen, Lars, Dennis, Mike, Craddock, Charles, Freeman, Sylvie, Clark, Richard E ORCID: 0000-0002-1261-3299 and Burnett, Alan K
(2022)
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.
HAEMATOLOGICA, 107 (7).
pp. 1518-1527.
Copland, Mhairi, Slade, Daniel, McIlroy, Graham, Horne, Gillian, Byrne, Jenny L, Rothwell, Kate, Brock, Kristian, De Lavallade, Hugues, Craddock, Charles, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 5 more authors)
(2022)
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
LANCET HAEMATOLOGY, 9 (2).
E121-E132.
Ferguson, Paul, Hills, Robert K, Grech, Angela, Betteridge, Sophie, Kjeldsen, Lars, Dennis, Michael, Vyas, Paresh, Goldstone, Anthony H, Milligan, Donald, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 2 more authors)
(2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
HAEMATOLOGICA, 101 (11).
pp. 1351-1358.